Print PDF

Subscribe

RSSAdd blog to your RSS reader

All Topics

Contact Us

212.451.2258

ADVERTISING@OLSHANLAW.COM

The Legal 500 Publishes “United States: Pharmaceutical Advertising” Q&A by Lustigman and Spina

The Legal 500 published a Q&A authored by attorneys Andrew Lustigman and Morgan Spina, entitled “United States: Pharmaceutical Advertising”

Olshan’s Advertising, Marketing & Promotions Practice Group chair Andrew Lustigman and associate Morgan Spina have authored the chapter “United States: Pharmaceutical Advertising” in The Legal 500: Pharmaceutical Advertising Country Comparative Guide, a country-specific Q&A providing an overview of pharmaceutical advertising laws and regulations applicable in the United States. Topics covered in the Q&A include how the advertising of medicines are regulated in the US, self-regulatory codes of practice applying to the advertising of medicines, how to define advertising for regulatory purposes, whether companies are required to have material approval prior to releasing a new drug, and more.

You can read the entire Q&A here.

Back to Page